Other Viruses Citation List: January 4 - January 17, 2013

HCMV

1. Novel Antiviral Activity of L-Dideoxy Bicyclic Nucleoside Analogues Versus Vaccinia and Measles Viruses in Vitro. McGuigan, C., K. Hinsinger, L. Farleigh, R.N. Pathirana, and J.J. Bugert. Journal of Medicinal Chemistry, 2013. [Epub ahead of print]; PMID[23320521].

[PubMed] OV_0104-011712.

Hepatitis B Virus

2. 2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) Prodrug: In Vitro anti-HBV Activity against the Lamivudine-Entecavir Resistant Triple Mutant and Its Mechanism of Action. Rawal, R.K., U.S. Singh, S.N. Chavre, J. Wang, M. Sugiyama, W. Hung, R. Govindarajan, B. Korba, Y. Tanaka, and C.K. Chu. Bioorganic & Medicinal Chemistry Letters, 2013. 23(2): p. 503-506; PMID[23237841].

[PubMed] OV_0104-011712.

Hepatitis C Virus

3. In Vitro Assessment of Drug-drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. Chu, X., X. Cai, D. Cui, C. Tang, A. Ghosal, G.H. Chan, M.D. Green, Y. Kuo, Y. Liang, C.M. Maciolek, J. Palamanda, R. Evers, and T. Prueksaritanont. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013. [Epub ahead of print]; PMID[23293300].

[PubMed] OV_0104-011712.

4. Ligand Design, Synthesis and Biological anti-HCV Evaluations for Genotypes 1B and 4A of Certain 4-(3- & 4-[3-(3,5-Dibromo-4-hydroxyphenyl)-propylamino]phenyl) butyric acids and 3-(3,5-Dibromo-4-hydroxyphenyl)-propylamino-acetamidobenzoic acid Esters. Ismail, M.A., K.A. Abouzid, N.S. Mohamed, and E.M. Dokla. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013. [Epub ahead of print]; PMID[23294107].

[PubMed] OV_0104-011712.

5. Direct-acting Antiviral Agents for Hepatitis C Virus Infection. Kiser, J.J. and C. Flexner. Annual Review of Pharmacology and Toxicology, 2013. 53: p. 427-449; PMID[23140245].

[PubMed] OV_0104-011712.

6. Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors. Nichols, D.B., R.A. Leao, A. Basu, M. Chudayeu, F.d.M.P. de, T.T. Talele, P.R. Costa, and N. Kaushik-Basu. Chemical Biology & Drug Design, 2013. [Epub ahead of print]; PMID[23311976].

[PubMed] OV_0104-011712.

Citations from the ISI Web of Knowledge Listings for O.V.

7. Identification of a New Mechanism of Non-Nucleoside Inhibition of HCV RNA-dependent RNA Polymerase by the Flavonoid Quercetagetin. Ahmed-Belkacem, A., R. Brillet, A. Florimond, N. Ahnou, C. Pallier, and J.M. Pawlotsky. Hepatology, 2012. 56: p. 298A-299A; ISI[000310955601213].

[WOS] OV_0104-011712.

8. TVB-2640, a Novel anti-HCV Agent, Safely Causes Sustained Host-target Inhibition in Vivo. Evanchik, M., H.Y. Cai, Q.S. Feng, L. Hu, R. Johnson, G. Kemble, Y. Kosaka, J. Lai, J.D. Oslob, M. Sivaraja, S. Tep, H.B. Yan, C.A. Zaharia, and R. McDowell. Hepatology, 2012. 56: p. 1066A-1067A; ISI[000310955603470].

[WOS] OV_0104-011712.

9. HDAC Inhibitors Are Potent Suppressors of HCV-induced Hepatocarcinogenesis by Upregulating MICA, a GWAS-Identified HCC Susceptibility Gene. Goto, K., R. Muroyama, N. Kowatari, R. Nakagawa, W.W. Li, and N. Kato. Hepatology, 2012. 56: p. 1075A-1075A; ISI[000310955603487].

[WOS] OV_0104-011712.

10. Enantioselective Synthesis of Derivatives and Structure-Activity Relationship Study in the Development of NA255 as a Novel Host-targeting anti-HCV Agent. Kawasaki, K., M. Masubuchi, T. Hayase, S. Komiyama, F. Watanabe, H. Fukuda, T. Murata, Y. Matsubara, K. Koyama, H. Shindoh, H. Sakamoto, K. Okamato, A. Ohta, A. Katsume, M. Aoki, Y. Aoki, N. Shimma, M. Sudoh, and T. Tsukuda. Bioorganic & Medicinal Chemistry Letters, 2013. 23(1): p. 336-339; ISI[000312267700062].

[WOS] OV_0104-011712.

11. Antiviral Activity and Resistance Profiles for ABT-267, a Novel HCV NS5A Inhibitor, in Vitro and During 3-Day Monotherapy in HCV Genotype-1 (GT1)-infected Treatment-naive Subjects. Krishnan, P., J. Beyer, G. Koev, T. Reisch, R. Mondal, D. Liu, J. Pratt, D.A. DeGoey, R. Wagner, C. Maring, W. Kati, A. Molla, A.L. Campbell, B. Bernstein, L. Williams, C. Collins, and T. Pilot-Matias. Hepatology, 2012. 56: p. 1069A-1069A; ISI[000310955603475].

[WOS] OV_0104-011712.

12. Antiviral Effetcts and Action Mechanisms of Novel N-(Morpholine-4-carbonyloxy) Amidine Compounds against Hepatitis C Virus. Kusano-Kitazume, A., N. Sakamoto, Y. Okuno, K. Mori, M. Nakagawa, S. Kakinuma, S. Nitta, M. Murakawa, S. Azuma, Y. Nishimura-Sakurai, A. Matsumoto, M. Hagiwara, Y. Asahina, and M. Watanabe. Hepatology, 2012. 56: p. 716A-716A; ISI[000310955602465].

[WOS] OV_0104-011712.

13. PPI-668, a Potent New Pan-genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety. Lalezari, J.P., G.C. Farrell, P.S. Shah, C. Schwab, D. Walsh, P. Vig, N.A. Brown, E. Ruby, S. Halfon, R. Colonno, L.P. Li, B. Johnston, W. Wargin, and E.J. Gane. Hepatology, 2012. 56: p. 1065A-1066A; ISI[000310955603468].

[WOS] OV_0104-011712.

14. Synthesis of Novel Amino-substituted N-Aryl benzamides as HA3G Stabilizer and Their Hepatitis C Virus Inhibitory Activities. Li, Y.P., Z.G. Peng, L.H. Hao, Z.Y. Wu, J.D. Jiang, and Z.R. Li. Hepatology, 2012. 56: p. 1077A-1077A; ISI[000310955603492].

[WOS] OV_0104-011712.

15. Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders with Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) with or without Peginterferon Alfa-2A/Ribavirin (PEG/RBV). Lok, A.S., D.F. Gardiner, C. Hezode, E. Lawitz, M. Bourliere, G.T. Everson, P. Marcellin, M. Rodriguez-Torres, S. Pol, L. Serfaty, T. Eley, S.P. Huang, M. Wind-Rotolo, F. McPhee, D.M. Grasela, and C. Pasquinelli. Hepatology, 2012. 56: p. 230A-231A; ISI[000310955601079].

[WOS] OV_0104-011712.

16. Miravirsen, a Novel anti-HCV Therapeutic Targeting the Host Cell Factor miR-122, Demonstrates Broad Antiviral Activity against Drug-resistant HCV Variants. Patick, A., K. Zeh, S. Ottosen, and M.R. Hodges. Hepatology, 2012. 56: p. 1070A-1070A; ISI[000310955603477].

17. Preclinical Evaluation of Asp5286, a Novel Cyclophilin Inhibitor with Potent anti-HCV Activity. Sawada, M., E. Tsujii, Y. Morishita, M. Uchida, K. Katsumata, K. Maki, T. Makino, S. Yoshimura, T. Yamanaka, G. Lund, N.M. Kneteman, and D.J.L. Tyrrell. Hepatology, 2012. 56: p. 1078A-1078A; ISI[000310955603493].

[WOS] OV_0104-011712.

18. Inhibition of Hepatitis C Virus Replication by Acyclic Retinoid. Shimakami, T., M. Honda, T. Shirasaki, S. Lemon, and S. Kaneko. Hepatology, 2012. 56: p. 713A-714A; ISI[000310955602460].

[WOS] OV_0104-011712.

19. Cell Penetrable Humanized-VH/VHH That Inhibit RNA Dependent RNA Polymerase (NS5B) of HCV. Thueng-in, K., J. Thanongsaksrikul, P. Srimanote, K. Bangphoomi, O. Poungpair, S. Maneewatch, K. Choowongkomon, and W. Chaicumpa. Plos One, 2012. 7(11): p. e49254; ISI[000312269500092].

[WOS] OV_0104-011712.

20. Discovery of AT26893, a Novel Allosteric Inhibitor of the Regulation of HCV NS3/4A Protein Function. Wilsher, N.E., M.G. Carr, J. Coyle, L. Fazal, B. Graham, C. Hamlett, S. Hiscock, H. Jhoti, A. Millemaggi, C. Murray, D. Norton, M. Reader, D. Rees, S.J. Rich, S. Saalau-Bethell, M. Sanders, N. Thompson, M. Vinkovic, H.M. Willems, and A. Woodhead. Hepatology, 2012. 56: p. 1079A-1080A; ISI[000310955603497].

[WOS] OV_0104-011712.

21. Interferon (IFN)-free Combination Treatment with the HCV NS3/4A Protease Inhibitor BI 201335 and the Non-nucleoside NS5B Inhibitor BI 207127 +/- Ribavirin (R): Final Results of Sound-C2 and Predictors of Response. Zeuzem, S., V. Soriano, T. Asselah, J.P. Bronowicki, A.W. Lohse, B. Mullhaupt, M. Schuchmann, M. Bourliere, M. Buti, S.K. Roberts, E.J. Gane, J.O. Stern, R. Vinisko, I. Herichova, W.O. Boecher, and F.J. Mensa. Hepatology, 2012. 56: p. 308A-309A; ISI[000310955601232].

[WOS] OV_0104-011712.